We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
Phillips-Medisize Corporation has announced the opening of its new design and development center in Suzhou, China. Growth of the company’s design and development centers supports its customers’ needs for patient-administered biologics, and pharmaceutical drug delivery and diagnostics device design and development services.
The creation of this new design and development center is in keeping with Phillips-Medisize’s long-standing global strategy of providing both regional manufacturing and outsourced design/development support for its global customers. Outsourced design and development services has proven to be important to the company’s customer base as it provides common worldwide quality standards and design controls while allowing for local service and manufacturing support.
As part of the company’s network of design and development centres, the Suzhou facility has multiple capabilities including device design, injection molding simulation, developmental tooling and assembly equipment, along with on-site programme management. This design and development group is actively working on multiple projects, including biologics drug delivery devices intended specifically for Asian markets.
In commenting on this new addition, Matt Jennings, chairman and CEO of Phillips-Medisize Corporation said: "This is a very exciting time for our customers and our company. The new Suzhou design and development centre, as part of our network, will support our customers’ need for outsourced design and develop of new market appropriate products for the Asian market."
The company’s network of four design centers located in North America, Europe and now Asia, employ approximately 200 engineering professionals, while the global programme management and new product introduction teams of 275 engineering professionals successfully drove the launch of 81 new products in 2014. Traditionally, over 80% of the new drug delivery, diagnostic, and med-tech products the company launches have their roots within the Phillips-Medisize design and development organisation.